肿瘤药学2025，Vol.15Issue(2)：259-263,5.DOI:10.3969/j.issn.2095-1264.2025.02.15
索拉非尼联合阿扎胞苷+低剂量CHG方案治疗难治复发FLT3-ITD阳性AML的临床疗效观察
Clinical observation of sorafenib combined with azacitidine and low-dose CHG regimen in the treatment of refractory/relapsed FLT3-ITD-positive AML
任欣欣 1韩晓辉 1赵洪波 1魏淑芳 1刘亚宁 1李焱1
作者信息
- 1. 邯郸市第一医院 血液内科,河北 邯郸,056000
- 折叠
摘要
Abstract
Objective To investigate the clinical efficacy of sorafenib combined with azacytidine and low-dose CHG(re-combinant human granulocyte colony stimulating factor+homoharringtonine+cytarabine)in the treatment of refractory/re-lapsed Fms-like tyrosine kinase 3-internal tandem duplication(FLT3-ITD)-positive acute myeloid leukemia(AML).Meth-ods Seventeen patients with refractory/relapsed FLT3-ITD-positive AML in our hospital between February 2020 and Febru-ary 2022 were selected as the research object.All patients were treated with sorafenib plus azacitidine and low-dose CHG reg-imen.The therapeutic effect and safety of the patients were analyzed,and the expression levels of FLT3 and nuclear transcrip-tion factor-κB(NK-κB)before and after treatment were compared.Results The overall response rate(ORR)was 82.35%.The main adverse reactions included myelosuppression and infections,all of which were resolved after treatment.Post-treatment FLT3 and NF-κB expression levels were significantly lower than pre-treatment levels(P<0.05).Conclusion The combination of sorafenib,azacitidine,and low-dose CHG demonstrates significant efficacy in treating refractory/relapsed FLT3-ITD-posi-tive AML,effectively reducing FLT3 gene expression levels,and is worthy of clinical application and promotion.关键词
急性髓系白血病/Fms样酪氨酸激酶3/索拉非尼/阿扎胞苷/高三尖杉酯碱/重组人粒细胞集落刺激因子Key words
Acute myeloid leukemia/Fms-like tyrosine kinase 3/Sorafenib/Azacitidine/Homoharringtonine/Recombi-nant human granulocyte colony stimulating factor分类
临床医学引用本文复制引用
任欣欣,韩晓辉,赵洪波,魏淑芳,刘亚宁,李焱..索拉非尼联合阿扎胞苷+低剂量CHG方案治疗难治复发FLT3-ITD阳性AML的临床疗效观察[J].肿瘤药学,2025,15(2):259-263,5.
